Rangwani Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 1.50 M
- Company Age 7 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.00 M
- Revenue Growth -44.55%
- Profit Growth 100.00%
- Ebitda 100.19%
- Net Worth 0.22%
- Total Assets 58.42%
About Rangwani Pharmaceuticals
Rangwani Pharmaceuticals Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 01 September 2017 (Seven years and five months 9 days old ). Its registered office is in Bhopal, Madhya Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M.
The company currently has active open charges totaling ₹6.00 M.
Anjali Rangwani, Deepak Rangwani, and Kiara Rangwani serve as directors at the Company.
Company Details
-
Location
Bhopal, Madhya Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51909MP2017PTC044065
-
Company No.
044065
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
01 Sep 2017
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Gwalior
Industry
What products or services does Rangwani Pharmaceuticals Private Limited offer?
Rangwani Pharmaceuticals Private Limited offers a wide range of products and services, including Esomeprazole Drugs, Esomeprazole Levosulpiride Capsule.
Who are the key members and board of directors at Rangwani Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anjali Rangwani
|
Director | 01-Sep-2017 | Current |
|
Deepak Rangwani
|
Director | 01-Sep-2017 | Current |
|
Kiara Rangwani
|
Director | 01-Sep-2017 | Current |
Financial Performance of Rangwani Pharmaceuticals.
Rangwani Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 44.55% decrease. The company also saw a substantial improvement in profitability, with a 100% increase in profit. The company's net worth moved up by a moderate rise of 0.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rangwani Pharmaceuticals?
In 2023, Rangwani Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Rangmouryas Agrotech Private LimitedAnjali Rangwani is a mutual person
Charges (Loans)
₹6.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.60 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Nov 2017 | Others | ₹6.00 M | Open |
How Many Employees Work at Rangwani Pharmaceuticals?
Unlock and access historical data on people associated with Rangwani Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rangwani Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rangwani Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.